Francois Brisebois analyst OPPENHEIMER

Currently out of the existing stock ratings of Francois Brisebois, 207 are a BUY (95.39%), 9 are a HOLD (4.15%), 1 are a SELL (0.46%).

Francois Brisebois

Work Performance Price Targets & Ratings Chart

Analyst Francois Brisebois, currently employed at OPPENHEIMER, carries an average stock price target met ratio of 39.84% that have a potential upside of 47.27% achieved within 245 days.

Francois Brisebois’s has documented 418 price targets and ratings displayed on 42 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on TARS, Tarsus Pharmaceuticals at 12-Aug-2026.

Wall Street Analyst Francois Brisebois

Analyst best performing recommendations are on DMTK (DERMTECH).
The best stock recommendation documented was for KALA (KALA PHARMACEUTICALS) at 4/14/2025. The price target of $15 was fulfilled within 142 days with a profit of $11.51 (329.8%) receiving and performance score of 23.23.

Average potential price target upside

AVDL Avadel Pharmaceuticals PLC DRRX Durect FLXN Flexion Therapeutics HRMY Harmony Biosciences Holdings ICAD icad inc KALA Kala Pharmaceuticals ACHV Achieve Life Sciences AQST Aquestive Therapeutics CMPS Compass Pathways Plc DMTK DermTech ICPT Intercept Pharmaceuticals OTIC Otonomy CYBN Cybin DMAC DiaMedica Therapeutics PCSA Processa Pharmaceuticals TARS Tarsus Pharmaceuticals SLP Simulations Plus MDWD Mediwound Ltd MNMD Mind Medicine BNGO Bionano Genomics DYN Dyne Therapeutics MDXH MDxHealth SA ADR SERA Sera Prognostics SVRA Savara CNTA Centessa Pharmaceuticals PLC ADR PRAX Praxis Precision Medicines TRDA Entrada Therapeutics AERI Aerie Pharmaceuticals BSGM BioSig Technologies, Common Stock CLSD Clearside Biomedical EBS Emergent Biosolutions GEMP Gemphire Therapeutics GLMD Galmed Pharmaceuticals Ltd NRBO Neurobo Pharmaceuticals SNSE Sensei Biotherapeutics ADVM Adverum Biotechnologies OVID Ovid Therapeutics ABEO Abeona Therapeutics AVD American Vanguard SBBP Strongbridge Biopharma plc SLNO Soleno Therapeutics NBY NovaBay Pharmaceuticals

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hold Since 03-Sep-2025

$22.5

$0.86 (3.97%)

$20

10 months 17 days ago
(20-Nov-2025)

3/3 (100%)

$-0.44 (-1.92%)

10

Hold Since 17-Nov-2025

10 months 20 days ago
(17-Nov-2025)

34/34 (100%)

$9.61 (102.34%)

366

Buy Since 06-Feb-2024

$20

$-1.64 (-7.58%)

$20

11 months 9 days ago
(28-Oct-2025)

4/5 (80%)

$1.41 (7.58%)

278

Buy Since 18-Jul-2025

$20

$-1.64 (-7.58%)

$22

11 months 14 days ago
(23-Oct-2025)

2/2 (100%)

$1.44 (7.76%)

71

Buy Since 30-Jun-2020

$20

$-1.64 (-7.58%)

$24

11 months 14 days ago
(23-Oct-2025)

10/18 (55.56%)

$1.44 (7.76%)

392

Show more analysts

Please expand the browser size to see the chart

Which stock is Francois Brisebois most bullish on?

Potential upside of $27 has been obtained for TARS (TARSUS PHARMACEUTICALS)

Which stock is Francois Brisebois most reserved on?

Potential downside of $8.1 has been obtained for CMPS (COMPASS PATHWAYS PLC)

What Year was the first public recommendation made by Francois Brisebois?

On 2017
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?